Experience

uMed

• Côte d'Ivoire
• Medical Practices
• 1 - 100 Employee

• VP / General Manager, North America

  • Jan 2018 - Present

  uMed connects Life Science organizations with a global network of health systems and providers for the creation of registries and clinical studies. We develop regulatory-quality registries and studies where patients can be compliantly re-engaged to support programs from drug discovery to post-market. The platform is free to providers, and providers are compensated for studies in which they participate. uMed connects Life Science organizations with a global network of health systems and providers for the creation of registries and clinical studies. We develop regulatory-quality registries and studies where patients can be compliantly re-engaged to support programs from drug discovery to post-market. The platform is free to providers, and providers are compensated for studies in which they participate.



mie-Health

• China
• Hospitals and Health Care

• Healthcare Operations and Clinical Consulting

  • Feb 2009 - Jan 2018

  Long and short term consulting engagements focused on designing / improving operations, leveraging and creating data sources, and identifying / implementing technology to deliver value-based care solutions, improved outcomes, and reduced costs. * Inverso Health - Diabetes technologies and reversal programs * New England Breath Technologies - non-invasive glucose monitoring device * Oncology Analytics - product development and operations revamp services for oncology prior authorization * BT Health – Leverage population health data at local and international levels for payor and pharma to improve targeting, research, and outcomes. * Inter3 – Design technology solutions for a “hospital-at-home” program * Andago, Novartis, Carematix, eQAPharma, Boston Scientific, Healthcentrix – o Global programs for biologics and devices (for payors and pharma) that improved compliance rates, performance, and clinical outcomes leveraging mobile technologies. o Designed and implemented innovative monitoring and data-feedback solutions for global clinical trials and post-market surveillance programs. Show less



McKesson

• United States
• Hospitals and Health Care
• 700 & Above Employee

• VP, International

  • Mar 2007 - Feb 2009

  Lead a matrixed team with P&L responsibility in the internationalization of care management software and services (InterQual, Disease Management) in hospital and payor organizations to improve outcomes and resource utilization. Grew business from 0 - $30 million through expansion of care management products into target markets. Lead a matrixed team with P&L responsibility in the internationalization of care management software and services (InterQual, Disease Management) in hospital and payor organizations to improve outcomes and resource utilization. Grew business from 0 - $30 million through expansion of care management products into target markets.



Hybridfour

• United Kingdom
• Software Development

• President \ General Manager

  • Jul 2005 - Jan 2007

  Lead the US and UK teams of this pharma-focused technology and consulting company in the development and delivery of patient-centered health and therapy support programs utilizing digital (mobile and web-based) technologies. Programs focused on high-value biologics / therapeutics. • Developed and implemented client-specific programs across a range of therapies and geographies using a combination of data collection (e.g., biometrics, QOL), incentives, personalized services, and targeted messaging and feedback. Programs created new data sources, and improved adherence, engagement, utilization and outcomes. Show less



Caremark

• United Kingdom
• Hospitals and Health Care

• VP, CarePatterns Population Health Management

  • Apr 2000 - Aug 2005

  General Manager of the CarePatterns population management business. Grew Full P&L accountability for operations, pricing, IT, program development, analytics, and sales. Provided health/condition management and pharma-sponsored therapy support. Programs improved adherence to therapy, clinical outcomes and reduced costs to payors. • Led diversification of client base, expanding from small employers to Fortune 100 organizations, payors, unions, government agencies and pharma. • Expanded programs from 5 (diabetes, heart disease COPD, heart failure, CAD) to over 20, including chronic pain, depression, rare conditions and wellness, incorporating consumer-focused and behavioral-based strategies. • First DM company to incorporate SMS to complement home-based devices. • Leveraged PBM pharma relationship to deliver pharma-sponsored programs Show less



Vasomedical

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• VP, International

  • 1996 - 2000

  Part of management team for start-up cardiovascular device company with new-to-market technology (EECP®). Developed and led pricing, approval and reimbursement efforts. Full P&L responsibility for US managed markets and international operations. Regularly present to investors. • Successfully reversed Medicare’s non-coverage policy to obtain reimbursement for EECP® therapy. Developed utilization and economic models for MCOs and single-payor markets. • Build and manage the Physician Advisory Council. • Coordinate research and trials work conducted outside the US. Markets included Japan, Europe (UK, Ireland, Germany, Italy, Spain), and Latin America (Colombia, Argentina, Brazil). Show less



Baxter Healthcare

• Australia
• 1 - 100 Employee

• Director, Business Development

  • 1989 - 1997

  * Developed market and integration strategies for non-traditional Baxter business lines for acquisition, licensing, and VC opportunities for biotech and renal businesses opportunities, including developing funding cases for start up business initiatives and strategic investments in start up ventures. * Setup and managed Baxter operations in emerging Latin American markets moving the business from distributor-directed to direct management. Full P&L responsibility for hospital supply and biotech product lines. Increased sales 20% and AGP 23%. * Led Government Affairs efforts as they related to market access for Baxter's products and services. Show less